417 related articles for article (PubMed ID: 3612533)
41. Inhibition by CV-3988 of the binding of [3H]-platelet activating factor (PAF) to the platelet.
Terashita Z; Imura Y; Nishikawa K
Biochem Pharmacol; 1985 May; 34(9):1491-5. PubMed ID: 2986648
[TBL] [Abstract][Full Text] [Related]
42. Effects of tetrandrine on rabbit platelet aggregation and platelet activating factor generation.
Zhang M; Zhang LZ; Lu JS
Zhongguo Yao Li Xue Bao; 1995 May; 16(3):209-12. PubMed ID: 7660812
[TBL] [Abstract][Full Text] [Related]
43. Species difference in the specific receptors of platelet activating factor.
Hwang SB; Lam MH
Biochem Pharmacol; 1986 Dec; 35(24):4511-8. PubMed ID: 3024653
[TBL] [Abstract][Full Text] [Related]
44. Inhibition of platelet activating factor by ajmaline in platelets: in vitro and in vivo studies.
Rahman NN; Simjee R; Faizi S; Atta-ur-Rahman ; Ali SS; Mahmood F; Saeed SA
Pak J Pharm Sci; 1991 Jan; 4(1):35-42. PubMed ID: 16414679
[TBL] [Abstract][Full Text] [Related]
45. Amifostine, a reactive oxigen species scavenger with radiation- and chemo-protective properties, inhibits in vitro platelet activation induced by ADP, collagen or PAF.
Porta C; Maiolo A; Tua A; Grignani G
Haematologica; 2000 Aug; 85(8):820-5. PubMed ID: 10942928
[TBL] [Abstract][Full Text] [Related]
46. Biological and pharmacological effects of pinusolide, a novel platelet activating factor antagonist.
Yang HO; Kang YH; Suh DY; Kim YC; Han BH
Planta Med; 1995 Dec; 61(6):519-22. PubMed ID: 8824945
[TBL] [Abstract][Full Text] [Related]
47. Mepyramine inhibits platelet activating factor-induced rabbit platelet aggregation: role of intracellular histamine.
Zeng S; Guo ZG
Zhongguo Yao Li Xue Bao; 1997 Mar; 18(2):155-8. PubMed ID: 10072970
[TBL] [Abstract][Full Text] [Related]
48. PAF, rather than histamine, participates in mouse anaphylactic hypotension.
Shibamoto T; Liu W; Cui S; Zhang W; Takano H; Kurata Y
Pharmacology; 2008; 82(2):114-20. PubMed ID: 18583921
[TBL] [Abstract][Full Text] [Related]
49. Pharmacological profile of TCV-309--a potent PAF antagonist.
Terashita Z; Takatani M; Nishikawa K
J Lipid Mediat; 1992; 5(2):183-5. PubMed ID: 1445598
[TBL] [Abstract][Full Text] [Related]
50. In vitro inhibitory effect of SR 27417, a potent platelet-activating factor (PAF) receptor antagonist, on the PAF-induced bovine platelet aggregation.
Bastos da Silva M; Delaunois A; Gustin P; Godeau JM; Lekeux P
Vet Res; 2000; 31(2):267-72. PubMed ID: 10779205
[TBL] [Abstract][Full Text] [Related]
51. In vitro and in vivo pharmacological profiles of the PAF receptor antagonist SRI 63-675.
Handley DA; Van Valen RG; Winslow CM; Tomesch JC; Saunders RN
Thromb Haemost; 1987 Apr; 57(2):187-90. PubMed ID: 3037718
[TBL] [Abstract][Full Text] [Related]
52. Design, synthesis, and structure-activity relationship studies of novel 1-[(1-acyl-4-piperidyl)methyl]-1H-2- methylimidazo[4,5-c]pyridine derivatives as potent, orally active platelet-activating factor antagonists.
Carceller E; Merlos M; Giral M; Balsa D; García-Rafanell J; Forn J
J Med Chem; 1996 Jan; 39(2):487-93. PubMed ID: 8558517
[TBL] [Abstract][Full Text] [Related]
53. Role of platelet-activating factor (PAF) in platelet accumulation in rabbit skin: effect of the novel long-acting PAF antagonist, UK-74,505.
Pons F; Rossi AG; Norman KE; Williams TJ; Nourshargh S
Br J Pharmacol; 1993 May; 109(1):234-42. PubMed ID: 8495241
[TBL] [Abstract][Full Text] [Related]
54. Species differences in platelet aggregation induced by platelet-activating factor (PAF).
Shinozaki K; Kawasaki T; Kambayashi J; Sakon M; Shiba E; Ou M; Mori T
Methods Find Exp Clin Pharmacol; 1992 Nov; 14(9):663-5. PubMed ID: 1294855
[TBL] [Abstract][Full Text] [Related]
55. An antagonistic activity of etizolam on platelet-activating factor (PAF). In vitro effects on platelet aggregation and PAF receptor binding.
Mikashima H; Takehara S; Muramoto Y; Khomaru T; Terasawa M; Tahara T; Maruyama Y
Jpn J Pharmacol; 1987 Aug; 44(4):387-91. PubMed ID: 2890779
[TBL] [Abstract][Full Text] [Related]
56. The isolation and characterization of kadsurenone from haifenteng (Piper futokadsura) as an orally active specific receptor antagonist of platelet-activating factor.
Shen TY; Hwang SB; Chang MN; Doebber TW; Lam MH; Wu MS; Wang X
Int J Tissue React; 1985; 7(5):339-43. PubMed ID: 2997065
[TBL] [Abstract][Full Text] [Related]
57. Human platelet aggregation and release reaction induced by platelet activating factor (PAF-acether)--effects of acetylsalicylic acid and external ionized calcium.
Cattaneo M; Canciani MT; Mannucci PM
Thromb Haemost; 1985 Apr; 53(2):221-4. PubMed ID: 3927505
[TBL] [Abstract][Full Text] [Related]
58. Antibodies to platelet-activating factor (PAF) inhibit PAF-induced platelet aggregation.
Smal MA; Cooney SJ; Baldo BA
J Lipid Mediat; 1991 Nov; 4(3):333-41. PubMed ID: 1764578
[TBL] [Abstract][Full Text] [Related]
59. Bioactive amide of prostaglandin E1 and ethanolamine plasmalogen analog of platelet-activating factor inhibits several pathways of human platelet aggregation.
Kulikov VI; Muzya GI
Biochemistry (Mosc); 2000 Apr; 65(4):427-30. PubMed ID: 10810178
[TBL] [Abstract][Full Text] [Related]
60. Platelet-released ADP stabilizes PAF-induced rabbit platelet aggregation by stabilizing intracellular calcium.
Yi FX; Guo ZG
Zhongguo Yao Li Xue Bao; 1998 Jul; 19(4):379-82. PubMed ID: 10375790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
